Targeting Complement at the Time of Transplantation

  • Steven SacksEmail author
  • Julia Karegli
  • Conrad A. Farrar
  • Elham Asgari
  • Wilhelm Schwaeble
  • Wuding Zhou
  • Richard A. Smith
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)


Complement activation occurs in at least two phases when an organ is transplanted into a naive recipient: during reperfusion with recipient blood particularly when the donor organ has undergone a significant period of ischaemia and then during acute rejection once the recipient immune system has recognised the donor tissue as non-self. Both of these reactions are most obvious in the extravascular compartment of the transplanted organ and involve local synthesis of some of the key complement components as well as loss of controls that limit the activation of the pivotal component C3. In contrast, sensitised individuals with pre-existing circulating antibodies have an immediate reaction against the transplant organ that is also complement dependent but is enacted in the intravascular space. All three types of injury (ischaemia-reperfusion, acute rejection, hyperacute rejection) have a critical effect on transplant outcome. Here we discuss therapeutic strategies that are designed to overcome the impact of these factors at the start of transplantation with the aim of improving long-term transplant outcomes. These include the concept of treating the donor organ with modified therapeutic regulators that are engineered to be retained by the donor organ after transplantation and prevent inflammatory injury during the critical early period. By targeting the donor organ with anchored therapeutic proteins, the systemic functions of complement including host defence remain intact. The control of complement activation during the first stages of transplantation, including the possibility that this will reduce the capacity of the graft for stimulating the adaptive immune system, offers an important prospect for increasing the longevity of the transplant and offsetting demand on the limited supply of donor organs. It also provides a model in which the benefits and indications for localised therapy to maximise therapeutic efficiency and minimise the systemic disturbance may be instructive in other complement-related disorders.


Acute Rejection Complement Activation Donor Organ Delay Graft Function Lectin Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Botto M, Lissandrini D, Sorio C, Walport MJ (1992) Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes. J Immunol 149:1348–1355PubMedGoogle Scholar
  2. Colten HR, Ooi YM, Edelson PJ (1979) Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 332:482–490CrossRefGoogle Scholar
  3. Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817CrossRefGoogle Scholar
  4. Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ (2011a) Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 92:163–169CrossRefGoogle Scholar
  5. Damman J, Nijboer WN, Schuurs TA, Leuvenink HG, Morariu AM, Tullius SG, van Goor H, Ploeg RJ, Seelen MA (2011b) Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant 26:2345–2354CrossRefGoogle Scholar
  6. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, Buurman WA (2003) Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 170:3883–3889CrossRefGoogle Scholar
  7. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350CrossRefGoogle Scholar
  8. Dodd I, Mossakowska DE, Camilleri P, Haran M, Hensley P, Lawlor EJ, McBay DL, Pindar W, Smith RA (1995) Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expr Purif 6:727–736CrossRefGoogle Scholar
  9. Farrar CA, Zhou W, Lin T, Sacks SH (2006) Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 20:217–226CrossRefGoogle Scholar
  10. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, Kremmer E, Rosen FS, Carroll MC (1996) Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 157:549–556PubMedGoogle Scholar
  11. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A (1998) A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 10:1923–1930CrossRefGoogle Scholar
  12. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS (2008) Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation 86:1319–1321CrossRefGoogle Scholar
  13. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS (2008) Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759–1766CrossRefGoogle Scholar
  14. Lechler RI, Sykes M, Thomson AW, Turka LA (2005) Organ transplantation – how much of the promise has been realized? Nat Med 11:605–613CrossRefGoogle Scholar
  15. Lewis AG, Kohl G, Ma Q, Devarajan P, Kohl J (2008) Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 153:117–126CrossRefGoogle Scholar
  16. Li K, Feito MJ, Sacks SH, Sheerin NS (2006) CD46 (membrane cofactor protein) acts as a human epithelial cell receptor for internalization of opsonized uropathogenic Escherichia coli. J Immunol 177:2543–2551CrossRefGoogle Scholar
  17. Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 44:3866–3874CrossRefGoogle Scholar
  18. Li Q, Peng Q, Xing G, Li K, Wang N, Farrar CA, Meader L, Sacks SH, Zhou W (2010) Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol 21:1344–1353CrossRefGoogle Scholar
  19. Maraganore JM (1993) Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor. Adv Exp Med Biol 340:227–236CrossRefGoogle Scholar
  20. Melchionna T, Karegli J, Farrar CA, McVey JH, Dorling A, Sacks SH, Smith RAG (2010) Integrating cytotopic strategy in transplantation: (1) Design of locally-acting coagulation inhibitors for use with anti-complement therapeutics. Mol Immunol 47(13):2203, Ref Type: AbstractCrossRefGoogle Scholar
  21. Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, Kambham N, Lerut E, Salvatierra O, Butte AJ, Sarwal MM (2009) Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 20:1839–1851CrossRefGoogle Scholar
  22. Pantazis P, Kalyanaraman VS, Bing DH (1990) Synthesis of the third component of complement (C3) by lectin-activated and HTLV-infected human T-cells. Mol Immunol 27:283–289CrossRefGoogle Scholar
  23. Patel H, Smith RA, Sacks SH, Zhou W (2006) Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17:1102–1111CrossRefGoogle Scholar
  24. Peng Q, Li K, Patel H, Sacks SH, Zhou W (2006) Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 176:3330–3341CrossRefGoogle Scholar
  25. Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA, Sacks SH, Zhou W (2008) Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a–C3aR interaction. Blood 111:2452–2461CrossRefGoogle Scholar
  26. Peng Q, Li K, Wang N, Li Q, Asgari E, Lu B, Woodruff TM, Sacks SH, Zhou W (2009) Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol 183:6058–6068CrossRefGoogle Scholar
  27. Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH (1996) Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 149:2055–2066PubMedPubMedCentralGoogle Scholar
  28. Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582–587CrossRefGoogle Scholar
  29. Pratt JR, Jones ME, Dong J, Zhou W, Chowdhury P, Smith RA, Sacks SH (2003) Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 163:1457–1465CrossRefGoogle Scholar
  30. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265–1275CrossRefGoogle Scholar
  31. Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273–292PubMedPubMedCentralGoogle Scholar
  32. Rioux P (2001) TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2:364–371PubMedGoogle Scholar
  33. Roozendaal R, Carroll MC (2007) Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 219:157–166CrossRefGoogle Scholar
  34. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, Farrar CA, Sacks S, Lee H, Zhang M, Iwaki D, Takahashi M, Fujita T, Tedford CE, Stover CM (2011) Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 108:7523–7528CrossRefGoogle Scholar
  35. Selander B, Martensson U, Weintraub A, Holmstrom E, Matsushita M, Thiel S, Jensenius JC, Truedsson L, Sjoholm AG (2006) Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 116:1425–1434CrossRefGoogle Scholar
  36. Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30:1037–1041CrossRefGoogle Scholar
  37. Smith RA, Dodd I, Oldroyd RG, Harry J, Clark C, Rolan P, Dawes L (2001) Preclinical and clinical progression of a membrane-targeted complement regulator therapeutic. Mol Immunol 38:122, Ref Type: AbstractCrossRefGoogle Scholar
  38. Smith RAG, Koffman G, Chowdhury P, Smith KCG, Watson CJ, Nicholson ML, Zhou W, Sacks SH (2007) Membrane-localising complement inhibitors – clinical progress. Mol Immunol 44(16):3915, Ref Type: AbstractCrossRefGoogle Scholar
  39. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M (2008) Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753–760CrossRefGoogle Scholar
  40. Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH (2001) Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med 7:801–806CrossRefGoogle Scholar
  41. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:425–435CrossRefGoogle Scholar
  42. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH (1999a) Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol 10:69–76PubMedGoogle Scholar
  43. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH (1999b) Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 162:4336–4341PubMedGoogle Scholar
  44. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM (2006) Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116:357–368CrossRefGoogle Scholar
  45. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, Carroll MC (1996) Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 183:2343–2348CrossRefGoogle Scholar
  46. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146–151CrossRefGoogle Scholar
  47. Zhang M, Austen WG Jr, Chiu I, Alicot EM, Hung R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD Jr, and Carroll MC (2004). Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 101:3886CrossRefGoogle Scholar
  48. Zheng X, Feng B, Chen G, Zhang X, Li M, Sun H, Liu W, Vladau C, Liu R, Jevnikar AM, Garcia B, Zhong R, Min WP (2006) Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 6:2099–2108CrossRefGoogle Scholar
  49. Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, Kubo N, Wong A, Min LR, Budohn ME, Garcia B, Jevnikar AM, Min WP (2008) Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol 173:973–980CrossRefGoogle Scholar
  50. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH (2000) Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105:1363–1371CrossRefGoogle Scholar
  51. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH (2006) Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 107:2461–2469CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Steven Sacks
    • 1
    • 2
    Email author
  • Julia Karegli
    • 1
    • 2
  • Conrad A. Farrar
    • 1
    • 2
  • Elham Asgari
    • 1
    • 2
  • Wilhelm Schwaeble
    • 3
  • Wuding Zhou
    • 1
    • 2
  • Richard A. Smith
    • 1
    • 2
  1. 1.Division of Transplantation Immunology and Mucosal BiologyMRC Centre for TransplantationLondonUK
  2. 2.NIHR Comprehensive Biomedical Research CentreGuy’s & St Thomas’ NHS Foundation Trust and King’s College LondonLondonUK
  3. 3.Department of Infection, Immunity and InflammationUniversity of LeicesterLeicesterUK

Personalised recommendations